Citigroup has maintained its Buy recommendation for Arcus Biosciences (NYSE:RCUS). The average one-year price target for Arcus Biosciences is $43.86, with a range from $22.22 to $73.50. This represents a potential increase of 99.09% from its latest reported closing price of $22.03.
As of May 26, 2023, there are 469 funds or institutions reporting positions in Arcus Biosciences. The put/call ratio of RCUS is 0.41, indicating a bullish outlook.
Notable shareholders of Arcus Biosciences include iShares Core S&P Small-Cap ETF, which holds 3,803K shares representing 5.20% ownership of the company, Biotechnology Portfolio, which holds 3,193K shares representing 4.37% ownership, and Octagon Capital Advisors, which holds 2,172K shares representing 2.97% ownership. Citadel Advisors holds 1,766K shares representing 2.42% ownership, and recently increased its portfolio allocation in RCUS by 97.83% over the last quarter.
Arcus Biosciences is an oncology-focused biopharmaceutical company with four molecules in clinical development, including Etrumadenant, the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, AB680, the first small-molecule CD73 inhibitor to enter the clinic, Domvanalimab, an anti-TIGIT monoclonal antibody, and a new potential immuno-oncology backbone therapy.
Key filings for Arcus Biosciences can be found on the company’s website.
This article was originally published on Fintel, and the views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
